noratherapeutics.com
Home | Nora Therapeutics
http://www.noratherapeutics.com/index.php
NT100 mimics the biological activity of a naturally occurring protein in the female reproductive tract to optimize maternal-fetal tolerance. Nora Therapeutics Appoints Joseph L. Turner to Board of Directors. Trial is currently enrolling patients with Recurrent Miscarriage.
noratherapeutics.com
Recurrent Miscarriage | Nora Therapeutics
http://www.noratherapeutics.com/recurrent-miscarriage.php
More than 30 percent of all pregnancies result in a loss. For a significant percentage of couples, miscarriage is repetitive, and not sporadic. This condition is referred to as recurrent miscarriage and is defined by the American Congress of Obstetricians and Gynecologists (ACOG) as two or more miscarriages. An estimated 1-5 percent of women of reproductive age suffer from recurrent miscarriage. And many of these cases have no known cause. As a potential therapy to reduce the risk of miscarriage in women...
noratherapeutics.com
NT100 | Nora Therapeutics
http://www.noratherapeutics.com/pipeline.php
Nora's lead product, NT100, is a novel treatment that has been specifically designed and developed to reduce the likelihood of miscarriage in women with a history of recurrent miscarriage. In a randomized, double-blind, placebo controlled trial, NT100 was evaluated in pregnant women under FDA reviewed protocols. NT100 demonstrated a favorable safety profile and the appropriate induction of key cell types believed to be involved in maternal-fetal tolerance and recurrent miscarriage. If successful, NT100 w...
SOCIAL ENGAGEMENT